Cure My Disease

Don't miss your cure!

 Log in / Sign up

Probiotic drink trial for MS shows promise in small study

NCT ID NCT07304713

Symptom relief Sponsor: Sheffield Hallam University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether people with Multiple Sclerosis (MS) could take a probiotic drink daily for 12 weeks. 29 participants drank 70ml of the probiotic each day and completed online questionnaires, cognitive tests, and provided stool samples. The main goal was to see if the approach was feasible and acceptable, while also exploring potential effects on symptoms and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Jun 2023

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or over. * Living in the United Kingdom. * Self-reported clinical diagnosis of MS. Exclusion Criteria: * Symptom relapse or hospital admission in the prior four weeks. * Rapidly progressing MS defined as two of more disabling relapses in the last year. * Immunocompromised and requiring steroids (not including PwMS taking anti-CD20 monoclonal antibodies \[Ocrevus or Kesimpta\]). * Type 2 diabetes, Cardiovascular disease, kidney disease, chronic gastrointestinal tract health issues. * Pregnant or lactating. * Dysphagia. * Antibiotic use in the prior three months. * Pro-biotic use in the prior four weeks. * Use of food supplements which target gut health in the prior four weeks. * Medically advised not to use a probiotic.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Sheffield Hallam University

    Sheffield, South Yorkshire, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.